When looking for a place to grow a life sciences business over the long term, sometimes the biggest location isn't ...

Data drives decision-making at Aulos Bioscience. It's also driven the career trajectory of its CEO. On this week's episode of the Business of Biotech podcast, we get an introspective walk through Aron ...

Biopharma guru Allan Shaw speculates on the risks and benefits that the incoming Trump administration could bring to the industry.

Following a years-long Big Pharma retreat from the discovery and development of new drugs for psychiatric and mental health disorders, an expanding group of psychedelic drug developers -- and ...

Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...

Life Biosciences' Jerry McLaughlin and Forge Biologics' John Maslowski explain the importance of transparency and collaboration when encountering manufacturing speed bumps.

"A version of this article was published first on Hyman, Phelps & McNamara’s FDA Law Blog. It is republished here with permission." In November, President-Elect Trump announced his pick of Robert ...

Foresite Labs' Vik Bajaj, Ph.D. shares how massive data sets are essential to shortening drug development timelines and creating innovative therapeutics.

Woody Bryan, Ph.D. has founded several biotech companies during his career, and he explains how his journey from scientist to business development prepared him for the C-suite.

Jerry McLaughlin explains the vetting process he used to select Forge Biologics as a CDMO partner.

A robust quality culture in the biopharmaceutical sector is characterized by all members of the organization comprehending the significance of patient safety and recognizing how their individual roles ...